Otonomy Shares Sink After Stopping Mid-Stage Tinnitus Study

  • Otonomy Inc OTIC has announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all time points.
  • The 153-subject study did show a higher response rate than placebo in a prospectively defined patient subgroup with tinnitus duration of fewer than six months (population studied in Phase 1/2 trial). 
  • The overall results do not support further development of OTO-313.
  • Also Read: Otonomy Hearing Loss Candidate Shows Clinical Benefit On Multiple Efficacy Endpoints.
  • "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study," said David Weber, president & CEO of Otonomy. 
  • In addition to this trial, the company also reviewed preliminary top-line results for the one-month safety evaluation of higher and bilateral dosing of OTO-313. It did not observe a clear treatment benefit in light of the Phase 2 results. 
  • Hence, Otonomy will discontinue working on OTIC-313 and shift its focus to OTO-413 for hearing loss. 
  • Enrollment is complete for evaluating higher dosing with top-line results expected in Q4 of 2022.
  • Price Action: OTIC shares are down 60.8% at $0.56 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!